9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical ...

5 min read |The Huntington’s disease community’s unprecedented mobilization helped secure a high-priority FDA meeting to discuss the path forward for AMT-130.

Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data ...

6 min read | Most people with HD report sleep problems, & new research suggests sleep quality is linked to many aspects of living with the disease. Wearables tracked people with HD for a year & ...

In plain language. Written by scientists. For the global HD community. ⏱️6 min read | Most people with HD report sleep problems, & new research suggests sleep quality is linked to many aspects of ...

Doctors have been prescribing drugs to help manage Huntington’s disease (HD) symptoms like chorea (involuntary movements) and irritability for decades. But surprisingly, there are not many studies ...

If you’ve tried to follow Huntington’s disease (HD) clinical trials recently, you’ll know the feeling: so many trials, so many acronyms, and so many announcements. It’s a fantastic problem to have!

UniQure announced on January 9, 2026 that they have scheduled a Type A meeting with the FDA to discuss the approval pathway for AMT-130 in the United States. Type A meetings are urgent, high-priority ...